Suppr超能文献

鉴别发育不良结节与早期肝细胞癌:常规磁共振成像的应用。

Differentiation between dysplastic nodule and early-stage hepatocellular carcinoma: the utility of conventional MR imaging.

机构信息

Chen-Te Chou, Ran-Chou Chen, Department of Biomedical Imaging and Radiological Science, National Yang-Ming Medical University, Taipei 112, Taiwan.

出版信息

World J Gastroenterol. 2013 Nov 14;19(42):7433-9. doi: 10.3748/wjg.v19.i42.7433.

Abstract

AIM

To elucidate the variety of ways early-stage hepatocellular carcinoma (HCC) can appear on magnetic resonance (MR) imaging by analyzing T1-weighted, T2-weighted, and gadolinium-enhanced dynamic studies.

METHODS

Seventy-three patients with well-differentiated HCC (wHCC) or dysplastic nodules were retrospectively identified from medical records, and new histological sections were prepared and reviewed. The tumor nodules were categorized into three groups: dysplastic nodule (DN), wHCC compatible with Edmondson-Steiner grade I HCC (w1-HCC), and wHCC compatible with Edmondson-Steiner grade II HCC (w2-HCC). The signal intensity on pre-contrast MR imaging and the enhancing pattern for each tumor were recorded and compared between the three tumor groups.

RESULTS

Among the 73 patients, 14 were diagnosed as having DN, 40 were diagnosed as having w1-HCC, and 19 were diagnosed as having w2-HCC. Hyperintensity measurements on T2-weighted axial images (T2WI) were statistically significant between DNs and wHCC (P = 0.006) and between DN and w1-HCC (P = 0.02). The other imaging features revealed no significant differences between DN and wHCC or between DN and w1-HCC. Hyperintensity on both T1W out-phase imaging (P = 0.007) and arterial enhancement on dynamic study (P = 0.005) showed statistically significant differences between w1-HCC and w2-HCC. The other imaging features revealed no significant differences between w1-HCC and w2-HCC.

CONCLUSION

In the follow-up for a cirrhotic nodule, increased signal intensity on T2WI may be a sign of malignant transformation. Furthermore, a noted loss of hyperintensity on T1WI and the detection of arterial enhancement might indicate further progression of the histological grade.

摘要

目的

通过分析 T1 加权像、T2 加权像和钆增强动态研究,阐明早期肝细胞癌(HCC)在磁共振成像(MR)上的多种表现方式。

方法

从病历中回顾性地确定了 73 例分化良好的 HCC(wHCC)或发育不良结节患者,并制备和复查了新的组织学切片。将肿瘤结节分为三组:发育不良结节(DN)、与 Edmondson-Steiner 分级 I HCC 一致的 wHCC(w1-HCC)和与 Edmondson-Steiner 分级 II HCC 一致的 wHCC(w2-HCC)。记录每个肿瘤的磁共振成像平扫信号强度和增强模式,并比较三组肿瘤之间的差异。

结果

在 73 例患者中,14 例被诊断为 DN,40 例被诊断为 w1-HCC,19 例被诊断为 w2-HCC。DN 与 wHCC(P = 0.006)和 DN 与 w1-HCC(P = 0.02)之间的 T2 加权轴向图像(T2WI)上的高信号测量值具有统计学意义。其他影像学特征在 DN 与 wHCC 之间或 DN 与 w1-HCC 之间均无显著差异。w1-HCC 与 w2-HCC 之间 T1W 反相位成像(P = 0.007)和动态研究的动脉期增强(P = 0.005)上的高信号具有统计学意义。其他影像学特征在 w1-HCC 与 w2-HCC 之间无显著差异。

结论

在对肝硬化结节进行随访时,T2WI 上的信号强度增加可能是恶性转化的标志。此外,T1WI 上的高信号强度明显缺失和动脉期增强的检测可能提示组织学分级的进一步进展。

相似文献

4
MR features of regenerative nodules and dysplastic nodules in the cirrhotic liver.
J Huazhong Univ Sci Technolog Med Sci. 2005;25(5):601-3. doi: 10.1007/BF02896030.
7
The utility of gadoxetic acid-enhanced MR imaging to characterize atypical cirrhotic nodules detected on dynamic CT images.
PLoS One. 2014 Oct 13;9(10):e107869. doi: 10.1371/journal.pone.0107869. eCollection 2014.

引用本文的文献

1
Distinguishing Hepatocellular Carcinoma from Cirrhotic Regenerative Nodules Using MR Cytometry.
Cancers (Basel). 2025 Apr 1;17(7):1204. doi: 10.3390/cancers17071204.
5
Problematic lesions in cirrhotic liver mimicking hepatocellular carcinoma.
Eur Radiol. 2019 Sep;29(9):5101-5110. doi: 10.1007/s00330-019-06030-0. Epub 2019 Feb 20.
6
Microvascular Invasion in HCC: The Molecular Imaging Perspective.
Contrast Media Mol Imaging. 2018 Oct 4;2018:9487938. doi: 10.1155/2018/9487938. eCollection 2018.
7
CT-MRI LI-RADS v2017: A Comprehensive Guide for Beginners.
J Clin Transl Hepatol. 2018 Jun 28;6(2):222-236. doi: 10.14218/JCTH.2017.00062. Epub 2018 Feb 22.

本文引用的文献

1
Diagnostic imaging of hepatocellular carcinoma: recent progress.
Oncology. 2011;81 Suppl 1:73-85. doi: 10.1159/000333265. Epub 2011 Dec 22.
6
Hepatocellular nodules in liver cirrhosis: MR evaluation.
Abdom Imaging. 2011 Jun;36(3):282-9. doi: 10.1007/s00261-011-9692-2.
7
Management of hepatocellular carcinoma: an update.
Hepatology. 2011 Mar;53(3):1020-2. doi: 10.1002/hep.24199.
10
The 2008 Okuda lecture: Management of hepatocellular carcinoma: from surveillance to molecular targeted therapy.
J Gastroenterol Hepatol. 2010 Mar;25(3):439-52. doi: 10.1111/j.1440-1746.2009.06207.x.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验